HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and maintained a price target of $36.
August 09, 2024 | 9:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and maintained a price target of $36.
The reiteration of a Buy rating and the maintenance of a $36 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100